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ABSTRACT
Background: Inflammatory breast cancer (IBC) is the most aggressive form 
of locally-advanced breast cancer. Identification of new therapeutic targets is 
crucial. We previously reported MARCKS mRNA overexpression in IBC in the largest 
transcriptomics study reported to date. Here, we compared MARCKS protein 
expression in IBC and non-IBC samples, and searched for correlations between 
protein expression and clinicopathological features.
Results: Tumor samples showed heterogeneity with respect to MARCKS 
staining: 18% were scored as MARCKS-positive (stained cells ≥ 1%) and 82% 
as MARCKS-negative. MARCKS expression was more frequent in IBC (36%) than 
in non-IBC (11%; p = 1.4E−09), independently from molecular subtypes and 
other clinicopathological variables. We found a positive correlation between 
protein and mRNA expression in the 148/502 samples previously analyzed 
for MARCKS mRNA expression. MARCKS protein expression was associated 
with other poor-prognosis features in the whole series of samples such as 
clinical axillary lymph node or metastatic extension, high pathological grade,  
ER-negativity, PR-negativity, HER2-positivity, and triple-negative and HER2+ statutes. 
In IBC, MARCKS expression was the sole tested variable associated with poor MFS.
Materials and Methods: We retrospectively analyzed MARCKS protein 
expression by immunohistochemistry in 502 tumors, including 133 IBC and 
369 non-IBC, from Tunisian and French patients. All samples were pre-
therapeutic clinical samples. We searched for correlations between MARCKS 
expression and clinicopathological features including the IBC versus non-IBC  
phenotype and metastasis-free survival (MFS).
Conclusions: MARCKS overexpression might in part explain the poor prognosis 
of IBC. As an oncogene associated with poor MFS, MARCKS might represent a new 
potential therapeutic target in IBC.
      Research Paper
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INTRODUCTION
Inflammatory breast cancer (IBC) is the most 
aggressive form of locally-advanced breast cancer. 
Classified T4d in the AJCC (American Joint Committee 
on Cancer) staging system, IBC is clinically defined 
by signs of inflammation (erythema, edema, warming, 
“peau d’orange”) arising quickly and involving more 
than one-third of the breast [1]. IBC is associated with 
a high metastatic propensity, and despite the introduction 
of multimodality treatment, the 5-year survival remains 
around 50%, inferior to that observed in non-IBC. 
IBC differs from non-IBC at many other levels. At the 
epidemiological level, IBC is more frequent in geographic 
areas such as North Africa [1, 2]. At the pathological level, 
IBCs are more frequently than non-IBC associated with 
ductal type, axillary lymph node invasion, high grade, 
ER and PR-negativity and HER2-positivity. The presence 
of tumor emboli in dermal lymphatic vessels is the 
pathological hallmark of IBC, but is neither mandatory 
nor sufficient for diagnosis. At the molecular level, higher 
incidence of certain alterations has been reported in IBC, 
such as EGFR overexpression, TP53 mutations, high 
proliferation and angiogenesis levels, and overexpression 
of E-cadherin and eIFG4I (see [3] for review). 
To better understand the pathophysiology of IBC, 
high-throughput molecular profiling was applied during 
the two last decades to preclinical models and clinical 
samples, initially focused on mRNA expression profiling 
[4], then on other technologies [5, 6]. These studies 
showed that IBC is a heterogeneous disease comprising 
all molecular subtypes previously described in non-IBC, 
but with more frequent aggressive subtypes, and that a 
molecular signature of IBC may be established. In 2008, 
we and others founded the World IBC Consortium to 
foster collaboration between research groups focusing 
on IBC. The first project was to redefine the molecular 
profile of IBC using an unprecedented number of samples. 
We gathered gene expression profiles of 389 clinical 
tumor samples, including 137 IBC and 252 non-IBC, 
which remains by far the largest series of IBC samples 
ever analyzed [7]. That allowed for the first time to take 
into account in the supervised analysis the unbalance in 
term of molecular subtypes between IBC and non-IBC. 
We identified a robust 79-gene IBC expression signature 
independent from the molecular subtypes. Among the top 
three genes overexpressed in IBC versus non-IBC, was 
MARCKS, which encodes for the myristoylated alanine-
rich protein kinase C substrate. 
MARCKS is a substrate of protein kinase C 
(PKC) that shuttles between the plasma membrane 
and cytoplasm in a PKC phosphorylation-dependent 
manner. It is ubiquitously expressed in various tissues 
[8] and is involved in cell adhesion, motility through the 
regulation of the actin cytoskeleton, cytokine secretion, 
and phagocytosis of inflammatory cells [9]. In some 
tissues, MARCKS phosphorylation is regulated by other 
kinases such as RHO kinases and MAP kinases [10, 11], 
the activation of which has been linked to metastasis [12]. 
Several recent data have shown the involvement of 
MARCKS in cancer aggressiveness, notably metastatic 
process and therapeutic resistance [13–18], and the 
efficiency of therapeutic inhibition of MARCKS [19, 20]. 
Such data, combined with MARCKS overexpression in 
IBC versus non-IBC, suggested that MARCKS might be 
a relevant target in IBC.
Here, as a first step and to validate our initial 
observation, we evaluated and compared MARCKS 
protein expression in 133 IBC and 369 non-IBC tumor 
samples collected from French and Tunisian patients. 
Correlations were established between protein expression 
and clinicopathological features.
RESULTS
Breast cancer population and clinicopathological 
features
The clinicopathological features of all samples 
(N = 502), IBC (N = 133) and non-IBC (N = 369) 
separately, are shown in Table 1. Patients with IBC 
were younger than patients with non-IBC (p = 6.1E-10). 
IBC cases were higher clinical stage with more frequent 
axillary lymph node involvement (p = 3.5E-22) and 
metastasis at diagnosis (p = 1.8E-19). IBC samples 
showed more frequently than non-IBC samples pejorative 
pathological prognostic features: ductal type (p = 1.2E-05), 
high grade (p < 1.0E-06), ER-negativity (p = 5.7E-04), 
PR-negativity (p = 1.3E-02), and HER2-positivity 
(p = 2.1E-17). Finally, the 5-year MFS was 53% (95% 
CI, 43–66) in patients with IBC and 81% (95% CI, 77–85) 
in patients with non-IBC (p = 1.3E-11). Altogether, these 
observations confirmed the clinical coherence of our series.
MARCKS protein expression in breast cancer
Before analysis of tissue samples, we validated the 
MARCKS antibody using western blot analysis on three 
breast cancer cell lines with known mRNA expression. 
As shown in Supplementary Figure S1, the antibody 
specifically recognized MARCKS protein with a good 
correlation between protein and mRNA expression levels. 
MARCKS expression was then measured on the 502 tumor 
samples. Examples of staining are shown in Figure 1. 
The staining was observed mainly in tumor cells and to 
a lesser degree in stroma, notably fibroblasts, whereas 
it was only weakly expressed in normal epithelial cells. 
Tumor cell staining was mainly located in the cytoplasm, 
but, in some samples, some staining was observed on the 
cytoplasmic membrane. No correlation was established 
between this membrane staining and clinical features. 
There was high heterogeneity between breast cancers with 
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respect to MARCKS staining (Table 2). The percentage of 
positively stained tumor cells ranged from 0% to 100%, 
with a median of 0%; 82% of samples showed 0% of 
stained tumor cells, 7% showed 1 to 25% of stained tumor 
cells, 3% showed 26 to 50% of stained tumor cells and 
51 to 75% of stained tumor cells, and 5% showed 76 to 
100% of stained tumor cells. Examples of staining are 
shown in Figure 1. In IBC samples, MARCKS staining 
Table 1: Clinicopathological characteristics of breast cancer samples
Characteristics All
Type
p-value*
non-IBC IBC
Median age, years (range) 54.5 (15–93.76) 58.29 (24.55–93.76) 49 (15–81) 6.06E-10
TNM, N  3.53E-22
0 287 (59%) 261 (71%) 26 (21%)
1,2,3 200 (41%) 105 (29%) 95 (79%)
TNM, M  4.16E-15
0 458 (94%) 364 (99%) 94 (78%)
1 28 (6%) 2 (1%) 26 (22%)
Pathological type  1.20E-05
ductal 369 (75%) 256 (70%) 113 (90%)
lobular 56 (11%) 48 (13%) 8 (6%)
mixed 17 (3%) 17 (5%) 0 (0%)
other 49 (10%) 45 (12%) 4 (3%)
Pathological grade  < 1.00E-06
1 127 (26%) 119 (33%) 8 (7%)
2 188 (39%) 149 (41%) 39 (33%)
3 168 (35%) 97 (27%) 71 (60%)
Pathological tumor size, pT  
pT1 147 (41%) 147 (41%) NR
pT2 149 (42%) 149 (42%) NR
pT3 59 (17%) 59 (17%) NR
Pathological axillary node status, pN  
negative 177 (50%) 177 (50%) NR
positive 175 (50%) 175 (50%) NR
ER IHC status  5.70E-04
negative 130 (27%) 82 (22%) 48 (39%)
positive 359 (73%) 284 (78%) 75 (61%)
PR IHC status  1.26E-02
negative 179 (37%) 122 (33%) 57 (46%)
positive 310 (63%) 244 (67%) 66 (54%)
HER2 IHC status  2.07E-17
negative 346 (83%) 295 (92%) 51 (52%)
positive 72 (17%) 25 (8%) 47 (48%)
Molecular subtype  < 1.00E-06
TN 58 (14%) 44 (14%) 14 (14%)
HR−/HER2+ 33 (8%) 12 (4%) 21 (21%)
HR+/HER2− 288 (69%) 251 (78%) 37 (38%)
 HR+/HER2+ 39 (9%) 13 (4%) 26 (27%)  
*, comparison IBC versus non-IBC; NR: not relevant.
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was observed in some cases within the dermal tumor 
emboli (Figure 1E). Using 1% of stained tumor cells as 
positivity cut-off, 89 samples (18%) exhibited a positive 
MARCKS expression (≥ 1% of stained cells), whereas 
413 (82%) were MARCKS-negative. The MARCKS 
staining intensity was also heterogeneous between all 
samples, ranging from null to strong, with a null median 
intensity; the intensity was null in 87% of cases, low in 
6%, moderate in 5%, and strong in 2%. Among the 502 
samples tested, 148 samples (34 IBC and 114 non-IBC) 
were previously analyzed for MARCKS mRNA expression 
on DNA microarrays [7]: as shown in Supplementary 
Figure S2, there was a correlation between protein and 
mRNA expression (p = 7.0E-03).
MARCKS protein expression and 
clinicopathological features
We searched for correlations between binary 
MARCKS IHC status and clinicopathological features 
of samples. As shown in Table 3, no correlation was 
found with patients’ age, pathological type, pathological 
tumor size, and pathological axillary lymph node status. 
Conversely, correlation was observed with other features: 
MARCKS-positivity was more frequently associated with 
clinical axillary lymph node positive status (p = 8.1E-03), 
metastatic stage (p = 4.0E-02), high grade (p = 5.0E-06), 
ER-negativity (p = 1.6E-08), PR-negativity (p = 6.4E-08), 
HER2-positivity (p = 1.5E-04), and triple-negative and 
HER2+ statutes (p < 1.0E-06). Importantly, MARCKS 
expression was more frequently positive in IBC than 
in non-IBC (p = 1.4E-09; Supplementary Figure S3A). 
Fifty-four percent of MARCKS-positive samples were 
IBC versus only 21% of MARCKS-negative samples 
(OR = 4.5; [95 CI, 2.7–7.5]). The percentage of 
MARCKS-positive cases was 36% in IBC versus 11% 
in non-IBC (Table 2), and was not different between 
the Tunisian and French IBC samples (42 versus 30%, 
p = 0.21; Supplementary Figure S3B). As shown in 
Table 2, the percentage of positively stained tumor cells, 
analyzed as continuous value and as discrete value in two 
or five subgroups) was significantly higher in IBC than 
in non-IBC. Similarly, the MARCKS staining intensity 
was significantly higher in IBC than in non-IBC, both as 
continuous and discrete values. 
Uni- and multivariate analyses of the IBC versus 
non-IBC distinction
Thus, MARCKS-positivity was associated with 
IBC phenotype. Because of association with other 
clinicopathological features, themselves known to be 
associated with the IBC/non-IBC distinction, we did uni- and 
multivariate analyses centered on the comparison IBC 
versus non-IBC (Table 4). In univariate analysis, as 
expected all tested variables (patients’ age, clinical lymph 
Figure 1: MARCKS immunostaining in breast cancer. (A–E) Representative images of IHC staining in IBC samples showing 
different percentage of expression: 0% (A), 1–25% (B), 26–50% (C), 56–75% (D), and 76–100% (E). A shows the negative membranous 
expression, whereas E shows strong cytoplasmic and membranous expression in tumor emboli. F-J/ Representative images of IHC staining 
in non-IBC samples: F show the negative membranous expression. F-J/ Representative images of IHC staining in non-IBC samples showing 
different percentage of expression: 0% (F), 1–25% (G), 26–50% (H), 56–75% (I), and 76–100% (J). F shows the negative membranous 
expression.
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node and metastatic extension, pathological type, grade, 
molecular subtypes, and MARCKS status) could distinguish 
IBC and non-IBC statutes. In multivariate analysis 
integrating all significant variables, MARCKS protein 
expression remained associated with the IBC phenotype 
(p = 6.9E-04), suggesting discriminating value independent 
from other variables including the molecular subtypes.
Uni- and multivariate prognostic analyses for 
MFS
We assessed the prognostic value of MARCKS 
expression in terms of MFS. MFS data were available 
for 458 non-metastatic (M0) patients, including 320 who 
remained metastasis-free during a median follow-up of 99 
Table 2: MARCKS IHC results in all breast cancer samples, in IBC and non-IBC
MARCKS IHC variable All BC(N = 502)
non-IBC
(N = 369)
IBC
(N = 133)
Odds Ratio
[95 CI] p-value**
Percentage of positive tumor cells
median (range) 0 (0–100) 0 (0–90) 0 (0–100) 1.55E-10
0% 413 (82%) 328 (89%) 85 (64%) 1.00E-06
1–25% 37 (7%) 16 (4%) 21 (16%)
26–50% 14 (3%) 5 (1%) 9 (7%)
51–75% 16 (3%) 7 (2%) 9 (7%)
76–100% 22 (5%) 13 (4%) 9 (7%)
negative (0%) 413 (82%) 328 (89%) 85 (64%) 4.5 [2.71–7.51] 1.42E-09
positive (1–100%) 89 (18%) 41 (11%) 48 (36%)
Staining intensity*
median (range) 0 (0–3) 0 (0–3) 0 (0–3) 9.63E-03
null 413 (87%) 328 (89%) 85 (79%) 4.93E-02
low 30 (6%) 21 (6%) 9 (8%)
moderate 25 (5%) 15 (4%) 10 (9%)
strong 8 (2%) 5 (1%) 3 (3%)
negative (null) 413 (87%) 328 (89%) 85 (79%) 2.1 [1.11–3.77] 1.48E-02
positive (low to strong) 63 (13%) 41 (11%) 22 (21%)
*N = 476; **p-value for the IBC vs non-IBC comparison.
Figure 2: Metastasis-free survival according to MARCKS expression in the whole population and in IBC and non-
IBC. (A) Kaplan-Meier MFS curves in patients with negative and positive expression in the whole population. (B) Similar to (A), but in 
patients with non-IBC (dashed lines) and patients with IBC (full lines). The p-values of log-rank test are indicated. 
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months (range, 5 to 231) and 138 who displayed metastatic 
relapse. The 5-year MFS rate was 76% [95 CI, 72–80]. In 
univariate analysis (Table 5), pathological type, clinical 
lymph node extension, high grade, IBC phenotype, and 
MARCKS expression (p = 1.5E-02, Wald test; HR = 1.67 
[95 CI, 1.10–2.53]) were associated with poor MFS. 
The 5-year MFS rate was 62% [95 CI, 51–75] in the 
MARCKS-positive group versus 78% [95CI, 74–83] in 
the MARCKS-negative group (p = 1.4E-02, log-rank test; 
Figure 2A). In multivariate analysis (Table 5), pathological 
type, clinical lymph node extension, grade, and IBC 
phenotype remained significant, whereas MARCKS 
expression lost its prognostic value (p = 0.163, Wald test; 
HR = 1.36 [95 CI, 0.88–2.10]).
Table 3: Clinicopathological correlations with MARCKS expression
Characteristics
MARCKS IHC
p-value
N negative positive
Median age, years (range) 494 54.88 (24.55−93.76) 54 (15−86.56) 0.136
TNM, N 8.07E-03
0 287 247 (62%) 40 (46%)
1,2,3 200 153 (38%) 47 (54%)
TNM, M 4.05E-02
0 458 383 (95%) 75 (89%)
1 28 19 (5%) 9 (11%)
Pathological type 0.175
ductal 369 298 (74%) 71 (82%)
lobular 56 48 (12%) 8 (9%)
mixed 17 17 (4%) 0 (0%)
other 49 41 (10%) 8 (9%)
Pathological grade 5.00E-06
1 127 116 (29%) 11 (13%)
2 188 164 (41%) 24 (29%)
3 168 119 (30%) 49 (58%)
Pathological tumor size, pT 0.204
pT1 147 132 (42%) 15 (34%)
pT2 151 127 (40%) 24 (55%)
pT3 61 56 (18%) 5 (11%)
Pathological axillary node status, pN 0.637
negative 184 163 (51%) 21 (46%)
positive 184 159 (49%) 25 (54%)
ER IHC status 1.58E-08
negative 130 85 (21%) 45 (52%)
positive 359 318 (79%) 41 (48%)
PR IHC status 6.37E-08
negative 179 125 (31%) 54 (63%)
positive 310 278 (69%) 32 (37%)
ERBB2 IHC status 1.47E-04
negative 346 296 (86%) 50 (67%)
positive 72 47 (14%) 25 (33%)
Molecular subtype < 1.00E-06
TN 58 37 (11%) 21 (28%)
HR−/HER2+ 33 19 (6%) 14 (19%)
HR+/HER2− 288 259 (76%) 29 (39%)
HR+/HER2+ 39 28 (8%) 11 (15%)
Type 1.42E-09
non-IBC 369 328 (79%) 41 (46%)
IBC 133 85 (21%) 48 (54%)
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The same analysis was then done in each clinical 
type separately, IBC and non-IBC (Table 5). In non-IBC 
(N = 364), the 5-year MFS rate was 81% (95 CI, 77–85) 
with 97 metastatic events, and the median follow-up 
was 111 months (range, 5 to 231). In univariate analysis, 
pathological type, tumor size, axillary lymph node status 
and grade were associated with MFS, whereas MARCKS 
expression was not (p = 0.825, Wald test; HR = 0.93 [95 
CI, 0.48–1.79]; Figure 2B). By contrast, in IBC (N = 94), 
MARCKS expression was associated with poor MFS 
(p = 3.9E-02, Wald test; HR = 1.93 [95 CI, 1.03–3.59], 
whereas the other tested prognostic factors were not. The 
5-year MFS rate was 35% [95 CI, 20–59] in the MARCKS-
positive group versus 64% [95 CI, 52–79] in the MARCKS-
negative group (p = 3.6E-02, log-rank test; Figure 2B).
DISCUSSION
Despite therapeutic progresses achieved during the 
last decades, the survival of patients with IBC remains 
unfavorable, and the identification of new therapeutic 
targets is crucial. Our objective was to validate at the 
protein level the overexpression of MARCKS in IBC in a 
large series of clinical samples (133 IBC and 369 non-IBC) 
and to search for correlations with tumor features. We 
showed that MARCKS expression was more frequent in 
IBC than non-IBC and was associated with poor-prognosis 
features in the whole series of samples. In IBC, MARCKS 
expression was associated with poor MFS.
We focused on MARCKS protein expression for 
several reasons: i) strong differential mRNA expression 
between IBC and non-IBC clinical samples in the largest 
transcriptomics study reported to date and stratified upon 
molecular subtypes [7]; ii) proven role of MARCKS 
in cancer progression including metastatic process 
and therapeutic resistance; iii) ongoing development 
of MARCKS inhibitors; iv) commercial availability 
of a corresponding monoclonal antibody performing 
sufficiently well in IHC on paraffin-embedded tissues 
as previously reported [18, 21]. Before analysis of tissue 
samples, we revalidated the antibody on breast cancer cell 
lines by using western blot analysis.
We found heterogeneous MARCKS staining 
between all breast cancers. Eighteen percent of cases were 
scored as MARCKS-positive and 82% as MARCKS-
negative. In the literature, only one study analyzed 
MARCKS protein expression in breast cancer using IHC 
in a series of 250 non-IBC spotted onto tissue microarrays 
[21]: MARCKS was first identified using proteomics as 
the fourth most upregulated protein in tamoxifen-resistant 
MCF7 breast cancer cells as compared to the MCF7 
parental cell line. Then, the knockdown of MARCKS in 
tamoxifen-resistant MCF7 cells was shown to decrease 
cell motility, whereas analysis of a panel of 21 breast 
cancer cell lines showed correlation of MARCKS mRNA 
and protein expression, as we observed here in our panel 
of three breast cancer cell lines and 148 clinical samples. 
Finally, IHC analysis with the same antibody and positivity 
cut-off (1% cut-off) as us in the present study showed 
a MARCKS-positive cytoplasmic staining in 40% of 
samples. The relative lower frequency of positivity that we 
found (18%) may be explained notably by the imperfect 
reproducibility of IHC and the heterogeneity of breast 
cancer. The same study also reported positive correlations 
between MARCKS-positivity and poor-prognosis features: 
metastatic stage, high grade, ER-negativity, PR-negativity, 
HER2-positivity, triple-negative and HER2+ statutes, 
as we found here in our larger series. Additionally, 
the authors showed positive correlation of MARCK 
expression with poor specific overall survival in all cases 
Table 4: Uni- and multivariate analyses of IBC/non-IBC distinction
Characteristics
Univariate Multivariate
N OR [95 CI] p-value N OR [95 CI] p-value
Age, years  494 0.95 [0.93–0.96] 2.68E-09 405 0.95 [0.93–0.97] 4.92E-04
TNM, N 1,2,3 vs. 0 487 9.08 [6.02–13.7] 9.88E-19 405 10.2 [5.24–19.7] 8.32E-09
TNM, M 1 vs. 0 486 50.3 [14.83–171] 1.33E-07 405 3.9E8 [0.00–Inf] 0.988
Pathological type lobular vs. ductal 491 0.38 [0.20–0.73] 1.45E-02 405 1.05 [0.33–3.39] 0.941
mixed vs. ductal 491 0 [0–Inf] 0.978 405 0 [0–Inf] 0.990
other vs. ductal 491 0.20 [0.08–0.48] 2.68E-03 405 0.25 [0.07–0.90] 0.075
Pathological grade 2 vs. 1 483 3.89 [1.99–7.61] 8.42E-04 405 1.61 [0.57–4.57] 0.450
3 vs. 1 483 10.9 [5.66–20.9] 1.85E-09 405 4.25 [1.53–11.8] 2.02E-02
Molecular subtype HR-/HER2+ vs. HR+/HER2− 418 11.9 [6.12–23.1] 7.86E-10 405 0.98 [0.42–2.31] 0.975
HR+/HER2+ vs. HR+/HER2− 418 13.6 [7.23–25.5] 9.40E-12 405 2.44 [0.98–6.06] 0.107
TN vs. HR+/HER2− 418 2.16 [1.21–3.86] 2.96E-02 405 8.93 [3.58–22.3] 8.32E-05
MARCKS IHC status positive vs. negative 502 4.52 [3.02–6.76] 7.53E-10 405 4.42 [2.15–9.09] 6.99E-04
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Table 5: Uni- and multivariate prognostic analyses for MFS
Characteristics
Univariate Multivariate
N HR [95 CI] p-value N HR [95 CI] p-value
All 
breast 
cancers
Age, years  458 0.99 [0.98–1.01] 0.24
Pathological type lobular vs. ductal 458 1.16 [0.72–1.88] 2.37E-02 452 1.70 [1.03–2.8] 3.69E-02
mixed vs. ductal 1.13 [0.52–2.42] 452 1.49 [0.68–3.27] 0.324
other vs. ductal 0.22 [0.08–0.61] 452 0.30 [0.11–0.83] 2.05E-02
TNM, N 1,2,3 vs. 0 457 2.52 [1.80–3.52] 7.88E-08 452 2.08 [1.46–2.98] 5.63E-05
Pathological grade 2 vs. 1 453 2.03 [1.24–3.33] 2.33E-06 452 1.69 [1.02–2.82] 4.34E-02
3 vs. 1 3.44 [2.11–5.60] 452 2.44 [1.45–4.11] 8.08E-04
Molecular subtype HR−/HER2+ vs. TN 394 1.46 [0.64–3.30] 0.161
HR+/HER2− vs. TN 0.79 [0.46–1.35]
HR+/HER2+ vs. TN 1.29 [0.61–2.73]
Type IBC vs. non-IBC 458 2.97 [2.04–4.31] 1.13E-08 452 1.96 [1.29–2.98] 1.63E-03
MARCKS IHC status positive vs. negative 458 1.67 [1.10–2.53] 1.56E-02 452 1.36 [0.88–2.10] 0.163
Characteristics
Univariate Multivariate
N HR [95 CI] p-value N HR [95 CI] p-value
IBC
Age, years  94 1.02 [1.00–1.05] 0.059
Pathological type lobular vs. ductal 94 1.13 [0.35–3.69] 0.666
mixed vs. ductal NA [ NA – NA]
other vs. ductal 0.41 [0.06–3.03]
TNM, N 1,2,3 vs. 0 93 1.66 [0.79–3.53] 0.184
Pathological grade 2 vs. 1 90 0.62 [0.18–2.05] 0.31
3 vs. 1 1.14 [0.40–3.25]
Molecular subtype HR−/HER2+ vs. TN 74 0.88 [0.25–3.07] 0.961
HR+/HER2− vs. TN 0.76 [0.27–2.16]
HR+/HER2+ vs. TN 0.81 [0.27–2.43]
MARCKS IHC status positive vs. negative 94 1.92 [1.03–3.59] 3.95E-02 94 1.92 [1.03–3.59] 3.95E-02
Characteristics
Univariate Multivariate
N HR [95 CI] p-value N HR [95 CI] p-value
non-IBC
Age, years  364 0.99 [0.98–1.01] 0.506
Pathological type lobular vs. ductal 364 1.39 [0.82–2.36] 2.83E-02 351 1.68 [0.97–2.93] 0.064
mixed vs. ductal 1.46 [0.67–3.17] 351 1.52 [0.69–3.34] 0.298
other vs. ductal 0.23 [0.07–0.74] 351 0.35 [0.11–1.12] 0.078
Pathological axillary 
node status, pN positive vs. negative 352 3.08 [1.95–4.87] 1.46E-06 351 2.25 [1.4–3.63] 8.246E-04
Pathological tumor 
size, pT pT2 vs. pT1 355 2.71 [1.62–4.53] 1.50E-05 351 1.78 [1.03–3.07] 3.724E-02
pT3 vs. pT1 3.83 [2.14–6.85] 351 2.51 [1.38–4.56] 2.593E-03
Pathological grade 2 vs. 1 363 2.25 [1.30–3.88] 7.45E-04 351 1.62 [0.91–2.88] 0.100
3 vs. 1 3.02 [1.70–5.37] 351 2.38 [1.27–4.44] 6.714E-03
Molecular subtype HR−/HER2+ vs. TN 320 1.27 [0.40–3.99] 0.909
HR+/HER2− vs. TN 0.91 [0.48–1.72]
HR+/HER2+ vs. TN 0.80 [0.22–2.88]
MARCKS IHC status positive vs. negative 364 0.93 [0.48–1.79] 0.825
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and in ER-positive cases in uni- and multivariate analyses. 
In our larger series, we confirmed the poor-prognosis value 
of MARCKS expression in breast cancer in univariate but 
not in multivariate analysis. The other study on MARCKS 
and breast cancer was recently published [22]. In small 
series of 21 and 50 breast tumors, including a majority of 
cancers, the authors showed frequent high IHC staining 
for phospho-MARCKS in breast cancer as compared to 
adjacent normal breast tissue and correlation with poor 
differentiation/high grade and metastatic status. Using 
both in vitro and in vivo models of triple-negative breast 
cancers, they then showed accumulation of phospho-
MARCKS in response to paclitaxel treatment and an 
increased paclitaxel sensitivity after reduction of phospho-
MARCKS by knockdown or by treatment with MANS 
peptide, a phospho-MARCKS inhibitor targeting the 
N-terminal myristoylation site. The MANS peptide also 
attenuated angiogenesis/metastasis of xenografted breast 
cancer cells. More recently, the unfavorable prognostic 
impact of high MARCKS mRNA expression on patients’ 
survival was found in a large annotated database of breast 
cancer patient samples [18]. Altogether, these studies 
suggested critical roles of MARCKS in the regulation of 
breast cancer aggressiveness, and therapeutic resistance, 
notably to hormone therapy and chemotherapy. In this 
context, the overexpression of MARCKS in IBC versus 
non-IBC seems coherent given the classical metastatic 
propensity and resistance of IBC. Interestingly, our 
multivariate analysis showed that the discriminating 
value of MARCKS expression between both phenotypes 
was independent from all other discriminating variables 
including the molecular subtypes (as previously 
observed at the mRNA level [7]) and the disease 
extension, suggesting that MARCKS expression per se 
represents a new discriminating feature. One possible 
mechanism of MARCKS overexpression in IBC might 
be the downregulation of miR-30b, a phosphoinositide 
3-kinase (PI3K)-targeting miRNA, which targets notably 
MARCKS [23]. Molecular profiling of experimental 
models with and without MARCKS activation could 
provide relevant insight about the regulation and the 
consequences of MARCKS expression in breast cancer. A 
more indirect way is to analyze gene expression profiles 
of clinical tumor samples according to MARCKS protein 
expression. From the 148 samples of our series for which 
gene expression data were also available, only 27 were 
MARCKS-positive, thus impeding any robust supervised 
analysis. We applied gene set enrichment analysis (GSEA) 
algorithm [24] to these 148 expression profiles and the 
674 Reactome gene sets (C2) of the MSigDB database. 
Analysis identified several significant gene sets (1000 
gene sets permutations, p < 0.05, FDR < 0.25) involved 
in cell proliferation, cell adhesion and immune response 
(Supplementary Figure S4). Interestingly, the unfavorable 
prognostic value of MARCKS expression for MFS was 
limited to IBC. 
Several studies in other solid cancers have suggested 
the involvement of MARCKS in tumor progression and 
resistance, and its interest as novel therapeutic target. By 
employing in vitro and in vivo approaches, Rombouts 
et al. showed an articulated role for MARCKS in the 
progression of colorectal cancer and suggested a suitable 
target to interfere and overcome the invasive behavior of 
colon carcinoma cells at primary and distant sites [15]. 
In melanoma, Chen et al. demonstrated that phospho-
MARCKS contributed to the metastatic potential of 
melanoma cells [13]. In cholangiocarcinoma, Techassen 
et al. showed in a series of 60 clinical samples that 
patients with high MARCKS expression had shorter 
survival than patients with low expression. Then, using 
experimental models, they reported MARCKS as one of 
the key players in the migration of cholangiocarcinoma 
cells and suggested that the cycling between MARCKS 
and phospho-MARCKS might regulate the metastasis of 
biliary cancer cells [16]. In ovarian carcinoma, in silico 
analysis of a large transcriptomic database showed that 
high MARCKS mRNA expression was associated with 
poor patient survival [18]. In a series of 10 normal ovarian 
tissues and 18 pairs of primary and metastatic epithelial 
ovarian cancer tissues analyzed by IHC, MARCKS protein 
was highly expressed in ovarian tumor stroma gradually as 
cancer progressed, and was required for the differentiation 
and tumor-promoting function of cancer-associated 
fibroblasts, including proliferation, chemotherapeutical 
resistance and migration in vitro. Analysis of MARCKS 
stromal staining intensity in our present series (data 
not shown) showed a moderate to strong expression in 
fibroblasts more frequent in IBC (31% of the samples) than 
in non-IBC (24% of the samples; p = 0.009, Fisher’s exact 
test), which might contribute to more cancer-associated 
fibroblasts activation in IBC and higher metastatic 
potential. In non-small-cell lung (NSCL) cancer, several 
studies suggested an oncogenic role for MARCKS. In a 
series of 99 patients with squamous cell carcinoma [14], 
a significant association was reported between positive 
IHC expression and poor survival. In another study [20], 
elevated levels of MARCKS and phospho-MARCKS 
were found in highly invasive lung cancer cell lines and 
clinical NSCL cancer samples. MARCKS knockdown 
reduced cell migration of highly invasive cancer cell lines 
and suppressed PI3K (phosphatidylinositol 3′-kinase)/AKT 
phosphorylation and SLUG level. Finally, treatment with 
the MANS peptide impaired cell migration in vitro and the 
metastatic potential of invasive lung cancer cells in vivo, 
through coordination of increase of E-cadherin expression, 
suppression of MARCKS phosphorylation and AKT/
SLUG signaling pathway. In a second study [19], higher 
phospho-MARCKS staining was associated with shorter 
survival in a series of 195 operated lung cancers and 
associated with EGFR-TKI-based treatment in a series of 
52 treated metastatic patients. In vitro models showed that 
phospho-MARCKS promoted cancer growth and erlotinib 
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resistance. Treatment with a 25-mer peptide targeting the 
MARCKS phosphorylation site domain (MPS peptide) 
suppressed tumor growth and metastasis in vivo, reduced 
levels of phospho-MARCKS and PIP3, and enhanced 
the sensitivity of lung cancer cells to erlotinib treatment 
in vitro and in vivo. These results indicated a crucial role 
for MARCKS, specifically its phosphorylated form, in 
potentiating lung cancer cell migration/metastasis/growth 
and suggested a potential use of MARCKS-related peptides 
in the treatment of lung cancer metastasis. Thus, our 
results (overexpression of MARCKS in IBC versus non-
IBC, association with poor-prognosis variables in breast 
cancers, unfavorable independent prognostic value in IBC) 
are consistent with the clinical and pre-clinical findings 
published in breast cancer and other cancers (colorectal, 
ovarian, lung, cholangiocarcinoma, melanoma). 
In conclusion, we showed a significant MARCKS 
protein overexpression in IBC when compared with non-
IBC, independent from other clinicopathological variables, 
and an association with poor MFS in IBC. The strengths 
of our study include the number of cases tested with a total 
of 502 breast cancers including 133 IBC, a tumor rare but 
aggressive; to our knowledge, it is the first study analyzing 
specifically MARCKS protein expression in IBC and 
the largest one in breast cancer. Our study provides a first 
independent validation of one of the key genes in the IBC-
specific 79-gene signature [7] and therefore lends credit to 
the signature as a whole to properly reflect IBC biology. 
Limitations include the retrospective nature and associated 
biases such as missing data with the absence of survival 
information for all patients. But yet, our results suggest 
that MARCKS overexpression might in part explain the 
poor prognosis of IBC and that MARCKS, as an oncogene 
associated with poor MFS in IBC, might represent a new 
potential target for therapeutic intervention. In this context, 
the assessment of MARCKS-related peptides such as MANS 
and MPS peptides in the treatment of IBC pre-clinical 
models is urgently warranted. The analysis of phospho-
MARCKS expression in our series is another relevant 
objective that might not only improve the discrimination 
between IBC and non-IBC when compared to MARCKS 
expression, but also improve the prognostic value and help 
predicting the response to MARCKS-related peptides.
MATERIALS AND METHODS
Patients and samples
In this retrospective study, we collected pre-
therapeutic diagnostic tumor samples from 133 patients 
with IBC treated at Institut Paoli-Calmettes (IPC) of 
Marseille (France; N = 69) and Institute Salah Azaiez 
of Tunis (Tunisia; N = 64). Main inclusion criteria 
were female patient, with clinically-defined and 
pathologically-confirmed IBC (AJCC T4d), written 
informed consent, available formaldehyde-fixed and 
paraffin-embedded pre-therapeutic diagnostic tumor 
sample and clinicopathological annotations. MARCKS 
immunohistochemistry (IHC) was done on standard slides. 
The study was approved by institutional review boards of 
the two participating centers. The control group included 
pre-therapeutic non-IBC samples from 369 women treated 
at IPC for a pathologically-confirmed invasive breast 
carcinoma, representing a mixture of early and advanced 
stages. Two tissue microarrays (TMA) were available for 
those 369 cases. They were constructed as previously 
described, with slight modifications [25]. For each sample, 
three representative tumor areas were carefully selected 
from a hematoxylin-eosin stained section of the donor 
block. Core cylinders with a diameter of 0.6 mm each 
were punched from each of these areas and deposited 
into the recipient paraffin block using a specific arraying 
device (Alphelys, Plaisir, France). Five-μm sections of 
the resulting TMA blocks were made and used for IHC. 
Clinicopathological annotations included patients’ age at 
diagnosis, TNM stage, pathological features (type, grade, 
tumor size and axillary lymph node status), ER, PR and 
HER2 IHC statutes, and clinical outcome. The molecular 
subtypes of tumors were based on ER, PR and HER2 IHC 
statutes and included four categories: HR+/HER2−, HR+/
HER2+, HR−/HER2+, and HR−/HER2−.
Immunohistochemical analysis 
MARCKS protein expression was analyzed 
on standard slides for the 133 IBC and TMAs for 
the 369 non-IBC using standard IHC protocols. IHC 
was performed on 4-μm sections. Paraffin sections 
were pretreated in PT Link PH6 (DakoCytomation, 
Copenhagen, Denmark). MARCKS staining was done 
with the rabbit monoclonal antibody, anti-MARCKS 
(D88D11) XP®Rabbit mAb#5607, from Cell Signaling 
Technology that was diluted at 1/400. We first validated 
the antibody using western blot analysis with breast cancer 
cell lines. Expression was analyzed in three breast cancer 
cell lines (T47D, SUM149, MDA-MB-231) previously 
profiled using Affymetrix DNA microarrays and for 
which MARCKS mRNA expression was documented as 
very low (T47D), moderate (SUM149), and very high 
(MDA-MB-231). Cells were washed 3 times with ice-
cold PBS and then resuspended for 30 min in 750 µl 
of ice cold lysis buffer containing 50 mM Hepes, pH 
7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1% 
Triton X-100, and 10% glycerol. A protease inhibitor 
mixture (Pierce) and the phosphotyrosyl phosphatase 
inhibitor sodium orthovanadate (BioLabs) were added 
as recommended. Lysates were heated in SDS sample 
buffer (60 mM Tris-HCl, pH 6.7, 3% SDS, 2% (v/v) 
2-mercaptoethanol, and 5% glycerol), separated by 10% 
SDS-PAGE, and transferred to nitrocellulose blotting 
membrane (Amersham). Membranes were blocked in 
PBS supplemented with BSA 5% and tween 0.1% for 
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1 h30 and then incubated overnight at 4°C with indicated 
antibodies. Visualization was done with ECL (Pierce). For 
the IHC analysis, the antigen was revealed by the Dako 
Flex system (Dako) using a peroxidase enzyme. Sections 
counterstained with hematoxylin were independently 
evaluated by two experienced breast pathologists (JTP 
and JJ) using light microscopy. Immunoreactivities were 
scored mainly by measuring the percentage of positive 
tumor cells, from 0% for undetectable level to 100% for 
total homogeneous staining. MARCKS-negative cases 
were defined by 0% level and positive cases by at least 
1% of stained tumor cells.
Statistical analysis
Data were summarized by numbers and percentages 
for categorical variables, and median and range for 
continuous variables. Correlations between tumor groups 
and clinicopathological features were analyzed using the 
t-test or the Fisher’s exact test when appropriate. Follow-
up was calculated from the date of diagnosis to the date of 
last news for event-free patients. Metastasis-free survival 
(MFS) was calculated from the date of diagnosis until the 
date of first distant relapse. Survival was calculated using 
the Kaplan-Meier method and curves were compared 
with the log-rank test. Uni- and multivariate analyses 
regarding the IBC/non-IBC distinction was done using 
logistic regression analysis using the glm function in R’s 
statistical package and the significance was estimated by 
specifying a binomial family for model with a logit link. 
Uni- and multivariate prognostic analyses for MFS were 
done using Cox regression analysis (Wald test). Variables 
with a p-value < 0.05 in univariate analysis were tested in 
multivariate analysis. All statistical tests were two-sided at 
the 5% level of significance. Analyses were done using the 
survival package (version 2.30) in the R software (version 
2.9.1; http://www.cran.r-project.org/). We followed 
the reporting REcommendations for tumor MARKer 
prognostic studies (REMARK criteria) [26].
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